Circulating levels and clinical significance of soluble GD40 in patients with hematologic malignancies

Cancer

Volumn 106, Issue 10, 2006, Pages 2148-2157

  Hock, Barry D ^a,e   McKenzie, Judith L ^a   Patton, Nigel W ^a   Drayson, Mark ^b   Taylor, Karen ^a   Wakeman, Chris ^a   Kantarjian, Hagop ^c   Giles, Francis ^c   Albitar, Maher ^c,d  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Acute myeloid leukemia; CD40; Chronic lymphocytic leukemia; Leukemia; Multiple myeloma; Prognosis

Indexed keywords

CD40 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CROSS LINKING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TUMOR IMMUNITY;

CD40 LIGAND; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA, MANTLE-CELL; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646344737     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21816     Document Type: Article

References (26)

1. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
2. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis. 2003;8:45-53.
3. Danese S, de la Motte C, Reyes Biol, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol. 2004;172:2011-2015.
4. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10:1-13.
5. Trentin L, Zambello R, Sancetta R, et al. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res. 1997;57:4940-4947.
6. Pope B, Brown RD, Gibson J, Yuen E, Joshua D. B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood. 2000;96:1274-1279.
7. Brouwer RE, Hoefnagel J, van Der Burg B, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CDl1a expression correlates with poor prognosis. Br J Haematol. 2001;115:298-308.
8. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:360-367.
9. Mackey MF, Gunn JR, Ting PP, et al. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res. 1997;57:2569-2574.
10. van Mierlo GJ, den Boer AT, Medema JP, et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA. 2002;99:5561-5566.
11. von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 1999;59:1287-1294.
12. Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19:3280-3287.
13. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917-2924.
14. Holler N, Kataoka T, Bodmer JL, et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods. 2000;237:159-173.
15. Fanslow WC, Anderson DM, Grabstein KH, Clark EA, Cosman D, Armitage RJ. Soluble forms of CD40 inhibit biologic responses of human B cells. J Immunol. 1992;149:655-660.
16. Schwabe RF, Engelmann H, Hess S, Fricke H. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol. 1999;117:153-158.
17. Contin C, Pitard V, Delmas Y, et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology. 2003;110:131-140.
18. Zhuang Y, Huang J, Zhou Z, et al. A novel blocking monoclonal antibody recognizing a distinct epitope of human CD40 molecule. Tissue Antigens. 2005;65:81-87.
19. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dechanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha- converting enzyme. Implications for CD40 signaling. J Biol Chem. 2003;278:32801-32809.
20. van Kooten C, Gaillard C, Galizzi JP, et al. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol. 1994;24:787-792.
21. Verstovsek S, Kantarjian H, Estey E, et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001;15:1165-1170.
22. Hock BD, Patton WN, Budhia S, Mannari D, Roberts P, McKenzie JL. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia. 2002;16:865-873.
23. Fawcett J, Holness CLL, Needham LA, et al. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature. 1992;360:481-484.
24. Hock BD, Starling GC, Patton WN, et al. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma. 2004;45:2111-2118.
25. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
26. Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004;101:999-1008.